» Articles » PMID: 20551155

Causes and Risk Factors for Death in Systemic Sclerosis: a Study from the EULAR Scleroderma Trials and Research (EUSTAR) Database

Abstract

Objectives: To determine the causes and predictors of mortality in systemic sclerosis (SSc).

Methods: Patients with SSc (n=5860) fulfilling the American College of Rheumatology criteria and prospectively followed in the EULAR Scleroderma Trials and Research (EUSTAR) cohort were analysed. EUSTAR centres completed a structured questionnaire on cause of death and comorbidities. Kaplan-Meier and Cox proportional hazards models were used to analyse survival in SSc subgroups and to identify predictors of mortality.

Results: Questionnaires were obtained on 234 of 284 fatalities. 55% of deaths were attributed directly to SSc and 41% to non-SSc causes; in 4% the cause of death was not assigned. Of the SSc-related deaths, 35% were attributed to pulmonary fibrosis, 26% to pulmonary arterial hypertension (PAH) and 26% to cardiac causes (mainly heart failure and arrhythmias). Among the non-SSc-related causes, infections (33%) and malignancies (31%) were followed by cardiovascular causes (29%). Of the non-SSc-related fatalities, 25% died of causes in which SSc-related complications may have participated (pneumonia, sepsis and gastrointestinal haemorrhage). Independent risk factors for mortality and their HR were: proteinuria (HR 3.34), the presence of PAH based on echocardiography (HR 2.02), pulmonary restriction (forced vital capacity below 80% of normal, HR 1.64), dyspnoea above New York Heart Association class II (HR 1.61), diffusing capacity of the lung (HR 1.20 per 10% decrease), patient age at onset of Raynaud's phenomenon (HR 1.30 per 10 years) and the modified Rodnan skin score (HR 1.20 per 10 score points).

Conclusion: Disease-related causes, in particular pulmonary fibrosis, PAH and cardiac causes, accounted for the majority of deaths in SSc.

Citing Articles

Distinct cAMP regulation in scleroderma lung and skin myofibroblasts governs their dedifferentiation via p38α inhibition.

Baas J, Varga J, Feghali-Bostwick C, Peters-Golden M, Fortier S bioRxiv. 2025; .

PMID: 40060695 PMC: 11888450. DOI: 10.1101/2025.02.26.640163.


Transthoracic Lung Ultrasound in Systemic Sclerosis-Associated Interstitial Lung Disease: Capacity to Differentiate Chest Computed-Tomographic Characteristic Patterns.

Rotondo C, Busto G, Rella V, Barile R, Cacciapaglia F, Fornaro M Diagnostics (Basel). 2025; 15(4).

PMID: 40002639 PMC: 11854868. DOI: 10.3390/diagnostics15040488.


Long-term cardiovascular outcomes after percutaneous coronary intervention in patients with systemic sclerosis.

Hirose K, Kiriyama H, Minatsuki S, Nagae Y, Furusawa T, Hiruma T Int J Cardiol Heart Vasc. 2025; 57:101625.

PMID: 39990173 PMC: 11847537. DOI: 10.1016/j.ijcha.2025.101625.


Arrhythmia as a Possible Complication of Mycophenolate Mofetil in Systemic Sclerosis: A Case Report.

Moradi Z, Ardestani V, Tamartash Z, Karimi E, Kavosi H Case Rep Med. 2025; 2025:8858671.

PMID: 39975771 PMC: 11839254. DOI: 10.1155/carm/8858671.


Cardiac Morpho-Functional Changes, Inflammation and Fibrosis in Systemic Sclerosis-A Pilot Study of a Tertiary Center Cohort.

Dorniak K, Gogulska Z, Viti A, Glinska A, Kulawiak-Galaska D, Fijalkowska J Diagnostics (Basel). 2025; 15(3).

PMID: 39941322 PMC: 11817609. DOI: 10.3390/diagnostics15030393.